Clinical Scorecard: How Regulatory Policy Shifts Affect Pharmacy Access to Mifepristone in Australia
At a Glance
Category
Detail
Condition
Medication abortion using mifepristone and misoprostol
Key Mechanisms
The study examined whether removing prescribing and dispensing restrictions was followed by changes in pharmacy ordering and geographic distribution of mifepristone-misoprostol, using monthly pharmacy sales records in an interrupted time-series analysis.
Target Population
The study assessed sales to community and hospital outpatient pharmacies in Australia.
Care Setting
Australian community and hospital outpatient pharmacies.
Key Highlights
Australia’s TGA approved the mifepristone-misoprostol regimen in 2012, subject to prescribing and dispensing restrictions.
On August 1, 2023, the TGA removed those restrictions; appropriately qualified and trained health care practitioners, including nurse practitioners and endorsed midwives, could prescribe, and any pharmacist could dispense.
The study compared monthly sales to community and hospital outpatient pharmacies over 24 months before and 24 months after the regulatory change.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Medication abortion represented nearly 50% of abortions in Australia in 2020.
The source describes mifepristone combined with misoprostol as a safe and effective medication abortion option, preferred by many individuals seeking abortion care.
Clinical Best Practices
The study used an interrupted time-series analysis of monthly sales to community and hospital outpatient pharmacies over equal 24-month periods before and after the August 2023 policy change.
